Facebook: Analysts Expect $3.03 In Q2 Earnings Per Share

Facebook (NASDAQ: FB) will be reporting its second quarter financial results today after the markets close. Analysts have a consensus $391.39 12-month price target on the company, via a total of 55 analysts, with 19 analysts having strong buy ratings. 27 analysts meanwhile have buy ratings, 7 have hold ratings, and two analysts have sell ratings on the company. The street high comes from Credit Suisse with a $480 price target, and the lowest target sits at $225 from Societe Generale.

38 analysts have revenue estimates for the second quarter. The mean revenue estimate between all 38 analysts is $27.87 billion; this number has been revised upwards from $24.28 billion at the start of the year. The highest revenue estimate is $28.75 billion, while the lowest is $27 billion.

Onto EBITDA estimates, there are currently 25 analysts who have second-quarter EBITDA estimates. The mean is currently $14.48 billion, with this number having been revised upwards from $11.78 billion at the start of the year. The street high estimate currently sits at $15.59 billion in EBITDA and the lowest is $12.36 billion.

Analysts estimate that quarterly earnings per share will come in at $3.03, with this number being revised upwards from $2.31 at the start of the year. Street high is $3.41 and the lowest estimate is $2.36 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A $2.2B Gold Project Is Outgrowing Its Plan | Michael Henrichsen – Gold X2 Mining

Pay for the Copper, Get the Gold Free | Rob McEwen – McEwen Inc

This Gold Discovery Was Already Huge. Now It’s Becoming a Monster. | Goliath Resources

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

BMO Expects Copper Production To Continue To Grow At Ivanhoe Mines

Ivanhoe Mines (TSX: IVN) earlier this week reported its quarterly production of copper. The company...

Friday, July 8, 2022, 02:21:00 PM

Denison Mines: Canaccord’s Take On The JCU Exploration Offer

Earlier this week, Denison Mines Corp. (TSX: DML) announced that they sent an offer to...

Friday, May 7, 2021, 10:15:00 AM

Zoom: Analysts Anticipate $906 Million In Q1 Revenues

Zoom Video Communications (NASDAQ: ZM) will be reporting their first quarter financial results June 1st...

Tuesday, June 1, 2021, 11:21:00 AM

Echelon Initiates Coverage On Freeman Gold With $1.10 Price Target

Yesterday, Echelon Partners initiated coverage on Freeman Gold Corp (CSE: FMAN) with a C$1.10 12-month...

Wednesday, December 2, 2020, 03:31:00 PM

Bill C-18: The Online News Act (…of sabotage!)

Lots of hand wringing in the corporate media as bill C-18, The Online News Act,...

Sunday, May 14, 2023, 09:00:00 AM